Evaluation of the usefulness of testing for p53 mutations in colorectal cancer surveillance for ulcerative colitis

American Journal of Gastroenterology

Volumn 94, Issue 2, 1999, Pages 456-462

  Lashner, Bret A ^a   Shapiro, Bradley D ^a   Husain, Asif ^a   Goldblum, John R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID; PROTEIN P53;

ADULT; ARTICLE; CANCER STAGING; COLON BIOPSY; COLORECTAL CANCER; CONTROLLED STUDY; DIET SUPPLEMENTATION; DYSPLASIA; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

ADULT; BIOPSY; COHORT STUDIES; COLITIS, ULCERATIVE; COLON; COLONOSCOPY; COLORECTAL NEOPLASMS; EVALUATION STUDIES; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MUTATION; PROGNOSIS; RISK FACTORS; TIME FACTORS;

EID: 0033082210     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.1999.877_f.x     Document Type: Article

References (51)

1. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: A population-based study. N Engl J Med 1990;323:1228-33.
2. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-68.
3. Lashner BA. Recommendations for colorectal cancer screening in ulcerative colitis: A review of research from a single university-based surveillance program. Am J Gastroenterol 1992;87:168-75.
4. Lashner BA. Cancer surveillance in ulcerative colitis: Much ado about little? In: Barkin JS, Rogers AL, eds. Difficult decisions in digestive diseases. St. Louis: Mosby, 1994:357-61.
5. Brentnall TA, Crispin DA, Rabinovitch PS, et al. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 1994; 107:369-78.
6. Lashner B A, Provencher KS, Seidner DL, et al. The effect of folie acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology 1997;112:29-32.
7. Lashner BA, Provencher K, Bozdech JM, et al. Worsening risk for the development of dysplasia or cancer in patients with chronic ulcerative colitis. Am J Gastroenterol 1995;90:377-80.
8. Lashner BA, Epstein SS. Industrial risk factors for colorectal cancer. Int J Health Serv 1990;20:459-83.
9. Lashner BA, Hanauer SB, Silverstein MD. Optimal timing of colonoscopy to screen for cancer in ulcerative colitis. Ann Intern Med 1988; 108:274-8.
10. Breslow NE, Day NE. Statistical methods in cancer research, vol 2: The design and analysis of cohort studies. Lyon: International Agency for Research in Cancer, 1987.
11. Collins RH, Feldman M, Fordtran JS. Colon cancer, dysplasia, and surveillance in patients with ulcerative colitis: A critical review. N Engl J Med 1987;316:1654-8.
12. Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994;343:71-4.
13. Connell WR, Lennard-Jones JE, Williams CB, et al. Factors affecting the outcome of endoscopie surveillance for cancer in ulcerative colitis. Gastroenterology 1994;107:934-44.
14. Lynch DAF, Lobo AJ, Sobala GM, et al. Failure of colonoscopic surveillance in ulcerative colitis. Gut 1993;34:1075-80.
15. Vemulapalli R, Lance P. Cancer surveillance in ulcerative colitis: More of the same or progress? Gastroenterology 1994;107:1196-9.
16. Connell WR, Talbot 1C, Harpaz N, et al. Clinicopathological characteristics of colorectal carcinoma complicating ulcerative colitis. Gut 1994:35:1419-23.
17. Melville DM, Jass JR, Morson BC, et al. Observer study of the grading of dysplasia in ulcerative colitis: Comparison with clinical outcome. Hum Pathol 1989;20:1008-14.
18. Riddell RH. Screening strategies in gastrointestinal cancer. Scand J Gastroenterol 1990;25(suppl 175): 177-84.
19. Rosenstock E, Farmer RG, Petras R, et al. Surveillance for colonic carcinoma in ulcerative colitis. Gastroenterology 1985;89:1342-6.
20. Ajioka Y, Watanabe H, Matsuda K. Over-expression of p53 protein in neoplastic changes in ulcerative colitis: Immunohistochemical study. J Gastroenterology 1995;30(suppl VIII):33-5.
21. Burmer GC, Crispin DA, Kolli VR, et al. Frequent loss of a p53 allele in carcinomas and their precursors in ulcerative colitis. Cancer Commun 1991:3:167-72.
22. Burmer GC, Rabinovitch PS, Haggitt RC, et al. Neoplastic progression in ulcerative colitis: Histology, DNA content, and loss of a p53 allele. Gastroenterology 1992; 103:1602-10.
23. Greenwald BD, Harpaz N, Yin J, et al. Loss of heterozygosity affecting the p53, Rb, and mcc/apc tumor suppressor gene loci in dysplastic and cancerous ulcerative colitis. Cancer Res 1992:52:741-5.
24. Harpaz N, Peck AL, Yin J, et al. p53 Protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma. Hum Pathol 1994:25:1069-74.
25. Taylor HW, Boyle M, Smith SC, et al. Expression of p53 in colorectal cancer and dysplasia complicating ulcerative colitis. Br J Surg 1993; 80:442-4.
26. Yin J, Harpaz N, Tong Y, et al. p53 Point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 1993:104: 1633-9.
27. Carson DA, Lois A. Cancer progression and p53. Lancet 1995;346: 1009-11.
28. Baas IO, Mulder JR, Offerhaus GJ, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
29. Costa A, Marasca R, Valentinis B, et al. p53 Gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. J Pathol 1995;176:45-53.
30. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal tumor development. N Engl J Med 1988;319:525-32.
31. Ilyas M, Talbot 1C. p53 Expression in ulcerative colitis: A longitudinal study. Gut 1995:37:802-4.
32. Auvinen A, Isola J, Visakorpi T, et al. Over-expression of p53 and long-term survival in colon carcinoma. Br J Cancer 1994:70:293-6.
33. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-8.
34. Pricolo VE, Finkelstein SD, Wu T-T, et al. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon. AmJ Surg 1996;171:41-6.
35. Remvikos Y, Tominaga O, Hammel P, et al. Increased p53 protein content of colorectal tumours correlates with poor survival. Br J Cancer 1992;66:758-64.
36. Starzynska T, Bromley M, Ghosh A, et al. Prognostic significance of p53 over-expression in gastric and colorectal carcinoma. Br J Cancer 1992;66:558-62.
37. Yamaguchi A, Kurosaka Y, Fushida S, et al. Expression of p53 protein in colorectal cancer and its relationship to short-term prognosis. Cancer 1992;70:2778-84.
38. Yamaguchi A, Nakagawara G, Kurosaka Y, et al. p53 Immunoreaction in endoscopie biopsy specimens of colorectal cancer and its prognostic significance. Br J Cancer I993;68:399-402.
39. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-21.
40. Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996;335:1727-32.
41. Provenzale D, Kowdley KV, Arora S, et al. Prophylactic colectomy or surveillance for chronic ulcerative colitis? A decision analysis. Gastroenterology 1995;109:1188-96.
42. Giovannucci E, Stampfer MJ, Colditz GA, et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 1993;85:875-84.
43. Freudenheim JL, Graham S, Marshall JR, et al. Folate intake and carcinogenesis of the colon and rectum. Int J Epidemiol 1991;20:368-74.
44. Lashner BA. Red Blood cell folate is associated with the development of dysplasia and cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993;119:549-54.
45. Lashner BA, Heidenreich PA, Su GL, et al. Effect of folate supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis. Gastroenterology 1989;97:255-9.
46. Elsborg L, Larsen L. Fotote deficiency in chronic inflammatory bowel disease. Scand J Gastroenterol 1979;14:1019-24.
47. Franklin JL, Rosenberg IH. Impaired folic acid absorption in inflammatory bowel disease: Effects of salicylazosulfapyridine (azulfidine). Gastroenterology 1973;64:517-25.
48. Halsted CH, Gandhi G, Tamura T. Sulfasalazine inhibits the absorption of folates in ulcerative colitis. N Engl J Med 1981;303:1513-7.
49. Seihub J, Dhar GJ, Rosenberg IH. Inhibition of folate enzymes by sulfasalazine. J Clin Invest 1978;61:221-4.
50. Cravo ML, Mason JB, Dayal Y, et al. Folate deficiency enhances the development of colonie neoplasia in dimethylhydrazine-treated rats. Cancer Res 1992;52:5002-6.
51. Kim Y-I, Pogribny IP, Basnakian AG, et al. Folate deficiency in rats induces DNA strand breaks and hypomethylation within the p53 tumor suppressor gene. Am J Clin Nutr 1997;65:46-52.